183 related articles for article (PubMed ID: 35749672)
1. Antibody-based therapy for acute myeloid leukemia: a review of phase 2 and 3 trials.
Thomas X; Elhamri M; Deloire A; Heiblig M
Expert Opin Emerg Drugs; 2022 Jun; 27(2):169-185. PubMed ID: 35749672
[TBL] [Abstract][Full Text] [Related]
2. Harnessing the Immune System Against Leukemia: Monoclonal Antibodies and Checkpoint Strategies for AML.
Masarova L; Kantarjian H; Garcia-Mannero G; Ravandi F; Sharma P; Daver N
Adv Exp Med Biol; 2017; 995():73-95. PubMed ID: 28321813
[TBL] [Abstract][Full Text] [Related]
3. Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats.
Williams BA; Law A; Hunyadkurti J; Desilets S; Leyton JV; Keating A
J Clin Med; 2019 Aug; 8(8):. PubMed ID: 31434267
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy for myelodysplastic syndrome and acute myeloid leukemia: where do we stand?
Spillane DR; Assouline S
Expert Rev Hematol; 2023; 16(11):819-834. PubMed ID: 37819154
[TBL] [Abstract][Full Text] [Related]
5. Acute myeloid leukemia and novel biological treatments: monoclonal antibodies and cell-based gene-modified immune effectors.
Tettamanti S; Magnani CF; Biondi A; Biagi E
Immunol Lett; 2013; 155(1-2):43-6. PubMed ID: 24076117
[TBL] [Abstract][Full Text] [Related]
6. Immune-Based Therapeutic Interventions for Acute Myeloid Leukemia.
Perna F; Espinoza-Gutarra MR; Bombaci G; Farag SS; Schwartz JE
Cancer Treat Res; 2022; 183():225-254. PubMed ID: 35551662
[TBL] [Abstract][Full Text] [Related]
7. Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross PF; Beitz J; Chen G; Chen XH; Duffy E; Kieffer L; Roy S; Sridhara R; Rahman A; Williams G; Pazdur R
Clin Cancer Res; 2001 Jun; 7(6):1490-6. PubMed ID: 11410481
[TBL] [Abstract][Full Text] [Related]
8. Novel monoclonal antibody-based therapies for acute myeloid leukemia.
Morsink LM; Walter RB
Best Pract Res Clin Haematol; 2019 Jun; 32(2):116-126. PubMed ID: 31203993
[TBL] [Abstract][Full Text] [Related]
9. Reinforcing the primary immunotherapy modulators against acute leukemia; monoclonal antibodies in AML.
Mahalleh M; Shabani M; Rayzan E; Rezaei N
Immunotherapy; 2019 Dec; 11(18):1583-1600. PubMed ID: 31841068
[TBL] [Abstract][Full Text] [Related]
10. Update on Immunotherapy in AML and MDS: Monoclonal Antibodies and Checkpoint Inhibitors Paving the Road for Clinical Practice.
Masarova L; Kantarjian H; Ravandi F; Sharma P; Garcia-Manero G; Daver N
Adv Exp Med Biol; 2018; 995():97-116. PubMed ID: 30539507
[TBL] [Abstract][Full Text] [Related]
11. Harnessing autologous immune effector mechanisms in acute myeloid leukemia: 2023 update of trials and tribulations.
Patel SA; Bello E; Wilks A; Gerber JM; Sadagopan N; Cerny J
Leuk Res; 2023 Nov; 134():107388. PubMed ID: 37729719
[TBL] [Abstract][Full Text] [Related]
12. Antibody-Based Treatment of Acute Myeloid Leukemia.
Garfin PM; Feldman EJ
Curr Hematol Malig Rep; 2016 Dec; 11(6):545-552. PubMed ID: 27734262
[TBL] [Abstract][Full Text] [Related]
13. Antibody Based Therapies in Acute Leukemia.
Shah NN
Curr Drug Targets; 2017; 18(3):257-270. PubMed ID: 27593687
[TBL] [Abstract][Full Text] [Related]
14. Monoclonal Antibodies in Acute Myeloid Leukemia-Are We There Yet?
Abaza Y; Fathi AT
Cancer J; 2022 Jan-Feb 01; 28(1):37-42. PubMed ID: 35072372
[TBL] [Abstract][Full Text] [Related]
15. Epigenetic targeting to enhance acute myeloid leukemia-directed immunotherapy.
Rausch J; Ullrich E; Kühn MWM
Front Immunol; 2023; 14():1269012. PubMed ID: 37809078
[TBL] [Abstract][Full Text] [Related]
16. The past and future of CD33 as therapeutic target in acute myeloid leukemia.
Laszlo GS; Estey EH; Walter RB
Blood Rev; 2014 Jul; 28(4):143-53. PubMed ID: 24809231
[TBL] [Abstract][Full Text] [Related]
17. Prospect of CAR T-cell therapy in acute myeloid leukemia.
Badar T; Manna A; Gadd ME; Kharfan-Dabaja MA; Qin H
Expert Opin Investig Drugs; 2022 Feb; 31(2):211-220. PubMed ID: 35051347
[TBL] [Abstract][Full Text] [Related]
18. An Update on the Clinical Evaluation of Antibody-Based Therapeutics in Acute Myeloid Leukemia.
Venugopal S; Daver N; Ravandi F
Curr Hematol Malig Rep; 2021 Feb; 16(1):89-96. PubMed ID: 33630233
[TBL] [Abstract][Full Text] [Related]
19. An evaluation of glasdegib for the treatment of acute myelogenous leukemia.
Thomas X; Heiblig M
Expert Opin Pharmacother; 2020 Apr; 21(5):523-530. PubMed ID: 32027196
[No Abstract] [Full Text] [Related]
20. Investigational CD33-targeted therapeutics for acute myeloid leukemia.
Walter RB
Expert Opin Investig Drugs; 2018 Apr; 27(4):339-348. PubMed ID: 29534618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
